Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
IL-36 receptor antagonist

Imsidolimab

An investigational treatment for Generalized Pustular Psoriasis.

Phase 3by Vanda Pharmaceuticals
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Imsidolimab wherever you encounter it, plus the key facts at a glance.

Generic name
Imsidolimab
Development code
ANB019
Drug class
IL-36 receptor antagonist
Manufacturer
Vanda Pharmaceuticals
How it's taken
In the pivotal trials a single intravenous dose of 300mg or 750mg was given to treat the flare, and people who improved then received 200mg injected under the skin every month, or a placebo, for up to 104 weeks.

An antibody for generalized pustular psoriasis that blocks the IL-36 receptor, the same target as Spevigo, under FDA review with a decision due December 12, 2026 under the proposed name Quimilza.

A single intravenous dose cleared or almost cleared the skin in 53% of patients at 4 weeks in the GEMINI trials, and Vanda reports that no flares occurred in patients on monthly maintenance doses, the longest treated for about 2 years.

Email me the day the FDA decides on Imsidolimab

The decision is expected by December 12, 2026. One email when it is public, with what it means in plain language, plus new trials for Generalized Pustular Psoriasis and FDA news. Unsubscribe anytime.

You'll get, for Generalized Pustular Psoriasis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Imsidolimab fits

If approved, imsidolimab would be the second IL-36 receptor antibody for GPP after Spevigo, which was approved in September 2022 for flares and in March 2024 for flare prevention.

  • The 2 have not been compared head to head.
  • The GEMINI data cover both roles, a single dose for an active flare and monthly dosing to prevent the next one, so the practical questions for patients and dermatologists will be the approved dose, dosing interval and cost once the label is known.

How Imsidolimab works

Generalized pustular psoriasis is driven by an overactive inflammation signal in the skin called the interleukin-36 pathway. Normally a protein called IL-36Ra keeps that pathway in check; in many people with GPP it is weak or missing, often because of a change in the IL36RN gene, and the pathway floods the skin with white blood cells that form pustules.

Imsidolimab is an antibody that sits on the IL-36 receptor so the signal cannot be delivered, acting as a substitute for the missing brake. It is the same strategy used by Spevigo (spesolimab), the first drug approved for GPP, and Vanda reports that it produced a low rate of antibodies against the drug itself in the trials.

Clinical trial results

In GEMINI-1, a single intravenous dose of imsidolimab left 53% of patients in each dose group (8 of 15) with clear or almost clear skin on the GPP Physician Global Assessment (GPPPGA 0/1) at week 4, compared with 13% on placebo (2 of 15)[3]. GEMINI-1 (NCT05352893) and GEMINI-2 (NCT05366855) were the pivotal efficacy studies, run at 26 sites in 11 countries according to the published paper[3], with 4 of the 45 GEMINI-1 participants enrolled in the United States according to ClinicalTrials.gov[1].

ClinicalTrials.gov lists GEMINI-1 as completed and GEMINI-2 as terminated in July 2024, ended after every participant had been treated for about 6 months, with the longest treated through 104 weeks[2]. Vanda reports that efficacy was maintained through an approximately 2-year maintenance period with monthly doses and that no flares occurred in the active treatment arm[4].

GEMINI-1 randomly assigned 45 adults with a flare, 15 each to a single 300mg or 750mg intravenous dose or placebo. GEMINI-2 then gave responders 200mg of imsidolimab or placebo under the skin every month, and partial responders 200mg openly, with safety up to 104 weeks as its main goal. The full data were published as Smieszek et al. in NEJM Evidence in 2026[3].

Side effects and safety

Early trial safety observations

Vanda describes the safety profile in GEMINI-1 and GEMINI-2 as favorable with a low incidence of anti-drug antibodies, and the full results were published in NEJM Evidence in April 2026. The paper reports that no serious adverse events led anyone to stop imsidolimab during up to 104 weeks of treatment[3]. The company's announcements do not list individual adverse event rates, and there is no US label yet.

For context, Spevigo, which blocks the same receptor, carries warnings about serious infections, tuberculosis screening, allergic and infusion reactions, and avoiding live vaccines; an imsidolimab label, if approved, would set its own warnings.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Imsidolimab

In the pivotal trials a single intravenous dose of 300mg or 750mg was given to treat the flare, and people who improved then received 200mg injected under the skin every month, or a placebo, for up to 104 weeks. The dose and schedule for patients will be set by the FDA label if it is approved.

Development history

Imsidolimab was developed by AnaptysBio, which licensed exclusive global rights to Vanda Pharmaceuticals. Vanda submitted the biologics license application and announced on February 25, 2026 that the FDA had accepted it with a target action date of December 12, 2026. Vanda's August 5, 2026 quarterly report refers to the product by the proposed brand name Quimilza, and its October 28, 2026 report says the application is still under review with the same December 12 date[7].

Japan's health ministry granted orphan designation in May 2026, and in July 2026 the European Medicines Agency's orphan drug committee adopted a positive opinion recommending orphan designation.

Ask anything about Imsidolimab
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Generalized Pustular Psoriasis trials

Other Generalized Pustular Psoriasis treatments

Common questions about Imsidolimab

▸What is Imsidolimab?

An antibody for generalized pustular psoriasis that blocks the IL-36 receptor, the same target as Spevigo, under FDA review with a decision due December 12, 2026 under the proposed name Quimilza. A single intravenous dose cleared or almost cleared the skin in 53% of patients at 4 weeks in the GEMINI trials, and Vanda reports that no flares occurred in patients on monthly maintenance doses, the longest treated for about 2 years.

▸How does Imsidolimab work?

Generalized pustular psoriasis is driven by an overactive inflammation signal in the skin called the interleukin-36 pathway. Normally a protein called IL-36Ra keeps that pathway in check; in many people with GPP it is weak or missing, often because of a change in the IL36RN gene, and the pathway floods the skin with white blood cells that form pustules. Imsidolimab is an antibody that sits on the IL-36 receptor so the signal cannot be delivered, acting as a substitute for the missing brake. It is the same strategy used by Spevigo (spesolimab), the first drug approved for GPP, and Vanda reports that it produced a low rate of antibodies against the drug itself in the trials.

▸What are the side effects of Imsidolimab?

Vanda describes the safety profile in GEMINI-1 and GEMINI-2 as favorable with a low incidence of anti-drug antibodies, and the full results were published in NEJM Evidence in April 2026. The paper reports that no serious adverse events led anyone to stop imsidolimab during up to 104 weeks of treatment[3]. The company's announcements do not list individual adverse event rates, and there is no US label yet. For context, Spevigo, which blocks the same receptor, carries warnings about serious infections, tuberculosis screening, allergic and infusion reactions, and avoiding live vaccines; an imsidolimab label, if approved, would set its own warnings.

▸How is Imsidolimab taken?

In the pivotal trials a single intravenous dose of 300mg or 750mg was given to treat the flare, and people who improved then received 200mg injected under the skin every month, or a placebo, for up to 104 weeks. The dose and schedule for patients will be set by the FDA label if it is approved.

▸Is Imsidolimab FDA approved?

Not yet. Imsidolimab is under FDA review for Generalized Pustular Psoriasis; Vanda Pharmaceuticals has filed an application and a decision is due December 12, 2026. The FDA calendar page tracks the outcome.

▸When will the FDA decide on imsidolimab?

The FDA's target action date for imsidolimab in generalized pustular psoriasis is December 12, 2026. Vanda announced the acceptance of its application on February 25, 2026.

▸Is imsidolimab FDA approved?

No. Vanda's October 28, 2026 quarterly release says the application is still under FDA review, with a target action date of December 12, 2026. Vanda plans to market it as Quimilza if approved.

▸How does imsidolimab compare to Spevigo?

Both are antibodies that block the IL-36 receptor. Spevigo has been approved since 2022 and has both an intravenous form for flares and a monthly under-the-skin injection for prevention. Imsidolimab's GEMINI trials used a single intravenous dose for the flare and a monthly injection under the skin afterwards, with 53% of patients clear or almost clear at week 4 versus 13% on placebo. The 2 drugs have not been compared in a trial.

More: Spevigo for GPP

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ClinicalTrials.gov. GEMINI-1: imsidolimab (ANB019) in generalized pustular psoriasis. https://clinicaltrials.gov/study/NCT05352893
  2. ClinicalTrials.gov. GEMINI-2: long-term safety and efficacy of imsidolimab (ANB019) in generalized pustular psoriasis. https://clinicaltrials.gov/study/NCT05366855
  3. NEJM Evidence · 2026-04-28. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. https://pubmed.ncbi.nlm.nih.gov/42047557/
  4. Vanda Pharmaceuticals via PR Newswire · 2026-02-25. Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html
  5. Vanda Pharmaceuticals via PR Newswire · 2026-04-28. Vanda Pharmaceuticals Announces the Publication of Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis in NEJM Evidence. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html
  6. Vanda Pharmaceuticals via PR Newswire · 2026-08-05. Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2026-financial-results-302844175.html
  7. Vanda Pharmaceuticals via PR Newswire · 2026-10-28. Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-third-quarter-2026-financial-results-302922677.html
  8. National Organization for Rare Disorders. Generalized Pustular Psoriasis. https://rarediseases.org/rare-diseases/generalized-pustular-psoriasis/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Imsidolimab by email

We'll email you when the FDA acts on Imsidolimab and when new trials for Generalized Pustular Psoriasis open. Unsubscribe anytime.

You'll get, for Generalized Pustular Psoriasis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site